Abstract
SARS-CoV-2 infection is generally mild or asymptomatic in children but the biological basis for this is unclear. We studied the profile of antibody and cellular immunity in children aged 3-11 years in comparison with adults. Antibody responses against spike and receptor binding domain (RBD) were high in children and seroconversion boosted antibody responses against seasonal Beta-coronaviruses through cross-recognition of the S2 domain. Seroneutralisation assays against alpha, beta and delta SARS-CoV-2 variants demonstrated comparable neutralising activity between children and adults. T cell responses against spike were >2-fold higher in children compared to adults and displayed a TH1 cytokine profile. SARS-CoV-2 spike-specific T cells were also detected in many seronegative children, revealing pre-existing responses that were cross-reactive with seasonal Alpha and Beta-coronaviruses. Importantly, all children retained high antibody titres and cellular responses at 6 months after infection whilst relative antibody waning was seen in adults. Spike-specific responses in children also remained broadly stable beyond 12 months. Children thus distinctly generate robust, cross-reactive and sustained immune responses after SARS-CoV-2 infection with focussed specificity against spike protein. These observations demonstrate novel features of SARS-CoV-2-specific immune responses in children and may provide insight into their relative clinical protection. Furthermore, this information will help to guide the introduction of vaccination regimens in the paediatric population.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was partly funded by UKRI/NIHR through the UK Coronavirus Immunology Consortium (UK-CIC). We acknowledge the support of the G2P-UK National Virology Consortium (MR/W005611/1) funded by the UKRI. The study was also funded in part by the MRC (MC UU 1201412).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
PHE Research Ethics Governance Group (reference NR0209; May 16, 2020)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Figure 4 now includes further evidence of cross reactive T cell responses in sero-negative children, E & F, cultured assay and pre-pandemic samples. Figure 5 has been modified and includes analysis of antibody and T cell responses in children at >12 months post-infection, including comparison of the stability of response between 6 and 12 months. Figure 6 now includes comparison of live SARS-CoV-2 neutralization in children and adults, including neutralization of Alpha, Beta and Delta variants. Pseudo-neutralization is also now shown in Extended Data Figure 3. Extended Data Figure 1. Now includes assessment of antibody responses in 35 convalescent confirmed SARS-CoV-2 PCR+ children. Showing MSD serology (Figure 1) is a robust method to identify prior infection. Modification to the text has also been included. Additional contributing authors have been included, related to the additional data.
Data Availability
Data is available following reasonable requests.
